StockData
Psyence Biomedical Ltd. logo

Psyence Biomedical Ltd. (PBMWW) stock

PBMWWNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBM
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 22, 2026Score 0/30
$0.01−0.00 (-2.50%)

Close on Oct 30, 2026Market cap –P/E –Yield –

Earnings

Psyence Biomedical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Psyence Biomedical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Psyence Biomedical has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Psyence Biomedical puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Psyence Biomedical filed with the SEC as exhibits to Form 8-K or 6-K

  1. PRESS RELEASE, DATED OCTOBER 5, 2026, TITLED "PSYENCE BIOMED PARTNERS WITH DEA-REGISTERED BENUVIA OPERATIONS TO ESTABLISH U.S. MANUFACTURE OF PHARMACEUTICAL-GRADE IBOGAINE."
    6-K
  2. PRESS RELEASE, DATED SEPTEMBER 28, 2026, TITLED "PSYENCE BIOMED ANNOUNCES EXCLUSIVE U.S. IBOGAINE LICENCE FOR TEXAS IBOGAINE RESEARCH CORPORATION."
    6-K
  3. PRESS RELEASE OF PSYENCE BIOMEDICAL LTD., DATED SEPTEMBER 23, 2026
    6-K
  4. PRESS RELEASE, DATED SEPTEMBER 14, 2026, TITLED "PSYENCE BIOMED ESTABLISHES TEXAS IBOGAINE RESEARCH CORPORATION TO ADVANCE U.S. IBOGAINE DEVELOPMENT."
    6-K
  5. INVESTOR PRESENTATION OF PSYENCE BIOMEDICAL LTD., DATED AUGUST 2026
    6-K
  6. PRESS RELEASE, DATED APRIL 23, 2026, TITLED "PSYENCE BIOMED INITIATES PATIENT DOSING IN PHASE IIB TRIAL EVALUATING NPX-5 FOR ADJUSTMENT DISORDER."
    6-K
  7. PRESS RELEASE, DATED APRIL 17, 2026, TITLED "PSYENCE BIOMED WELCOMES U.S. EXECUTIVE ACTION TO ADVANCE RESEARCH INTO IBOGAINE."
    6-K
  8. PRESS RELEASE, DATED APRIL 8, 2026, TITLED "PSYENCE BIOMED EXPANDS AUSTRALIAN CLINICAL SITE NETWORK TO FIVE SITES, ADVANCING NPX-5-SUPPORTED CLINICAL ACTIVITIES."
    6-K
  9. PRESS RELEASE, DATED FEBRUARY 20, 2026
    6-K
  10. PRESS RELEASE, DATED FEBRUARY 13, 2026
    6-K
  11. PRESS RELEASE, DATED FEBRUARY 13, 2026
    6-K
  12. PRESS RELEASE, DATED FEBRUARY 11, 2026
    6-K
  13. PRESS RELEASE, DATED JANUARY 28, 2026
    6-K
  14. PRESS RELEASE, DATED JANUARY 22, 2026
    6-K
  15. PRESS RELEASE, DATED JANUARY 14, 2026
    6-K